Prosecution Insights
Last updated: November 04, 2026
Application No. 17/774,089

SELF-EMULSIFYING CANNABINOID FORMULATION AND METHOD

Non-Final OA §103§112
Filed
May 03, 2022
Priority
Nov 04, 2019 — provisional 62/930,401 +1 more
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Landrace Bioscience Inc.
OA Round
3 (Non-Final)
41%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
410 granted / 1002 resolved
-19.1% vs TC avg
Strong +36% interview lift
Without
With
+35.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
75 currently pending
Career history
1091
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
62.8%
+22.8% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1002 resolved cases

Office Action

§103 §112
DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of t/e previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants’ submission filed on 5/22/2026 has been entered. Status of Application The Examiner acknowledges receipt of the amendments filed on 5/22/2026 wherein claim 1 has been amended and claim 29 has been cancelled. Claims 1-3, 5, 8, 10, 16, 21, 24, 27-28 and 31-34 are presented for examination on the merits. The following rejections are made. Response to Applicants’ Arguments Applicant’s amendment filed 5/22/2026 renders moot the rejection of claim 29 made by the Examiner under 35 USC 112(b). This rejection is withdrawn. Applicant’s amendment filed 5/22/2026 renders moot the rejection of claim 5 made by the Examiner under 35 USC 112(d). This rejection is withdrawn. Applicant’s arguments filed 5/22/2026 regarding the rejection of claims 1-3, 5, 8, 10, 16, 21, 24, 27, 28 and 31-34 made by the Examiner under 35 USC 103 over Smith et al. (US 2016/0303039) in view of Gizurarson et al. (US 2008/0275030) and Gumudavelli et al. (US 2018/0169061) have been fully considered but they are not found persuasive and is MAINTAINED for the reasons of record in the office action mailed on 10/17/2025. In regards to the 103 rejection, Applicant asserts the following: A) The claims have been amended to require that the composition use an oil-free cannabinoid or cannabinoid blend. This limitation distinguishes the invention from the prior art as the claimed invention is essentially free of oil and water. Regarding the cited art, Smith is directed to a transdermal composition which contains a surfactant-lecithin organogel and a cannabinoid. Smith’s composition system uses similar components for a different effect. Gumudavelli describes non-aqueous D9-THC oral compositions that form micelles in the gastrointestinal tract to improve absorption but not so robust as to prevent absorption of the active from the intestinal lumen which may include a variety of excipients. In response to A, the composition being essentially free of oil and water, as alluded to by Applicant, is not seen as a feature of the claimed invention. This is because a) the present claims are ‘comprising’ claims and would therefore be inclusive to unrecited ingredients, such as oils and water; and b) the claims do not stipulate that the composition is free from oil (and water) but instead that the cannabinoid is oil free. The amendment filed 5/22/2026 adds the provision that the cannabinoid be ‘oil free’ but the cannabinoid being oil free is entirely different from the composition being oil free. If the desire of the present invention is to be oil free, then the claim should reflect this limitation, e.g. ‘An oil free self-emulsifying pharmaceutical formulation’, ‘wherein the composition is free of oil and water’, or something similar. Regarding the prior art and the differences in effect, modes of activity and composition properties, these are acknowledged but not found persuasive. For instance, Smith’s THC composition being a transdermal formulation would not preclude one from modifying and improving that formulation with other known compositions. Gizurarson teaches that dimethyl isosorbide and b-cyclodextrin are used in cannabinoid compositions so as to enhance the solubility of poorly soluble substances (like cannabinoids) and improve absorption. Both outcomes would be desired additions to Smith’s composition and one of ordinary skill in the art would modify Smith accordingly to provide those additional benefits. Regarding the ability to self-emulsify, this property would be expected as a necessary outcome of the obvious composition. Upon arriving at a composition like that recited, that resulting composition would have the ascribed property, even if unrecognized by the prior art. However, the Examiner is not persuaded that such a property would be entirely unexpected given that Smith contemplates emulsions and the use of emulsifiers (see [0023]), Gizurarson contemplates emulsions (see [0066]) and Gumudavelli contemplates both self-emulsifying and emulsion compositions (see [0004, 0059]). If an emulsion may be formed, then it is reasonable to expect a derivative of that composition (such as that sought) to have the ability to produce an emulsion on its own. The ability of the present invention appears to be an outcome of providing the selected ingredients into an environment, e.g. gastrointestinal tract, suitable for inducing emulsification. In any case, the composition as claimed remains obvious as are the downstream properties. Applicant’s arguments are not considered persuasive. Rejections Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claim 1 is rejected under 35 U.S.C. 112(a) as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor at the time the application was filed had possession of the claimed invention. Amended claim 1 recites, “…oil free cannabinoid or a cannabinoid blend…” The underlined section has been added. However, this limitation appears to lack support in the specification as filed. A review of the specification did not show that Applicant was in possession of an ‘oil free’ cannabinoid. The term ‘oil’ is mentioned 9 times or so within the specification and most of those recitations are to ‘ethoxylated castor oil wax’ and never in relation to the cannabinoid component. Thus, the limitation to an oil free cannabinoid appears to lack written description. If Applicant contends that there is support for the limitation and/or that the Examiner has overlooked a feature of the specification, then Applicant is requested to point to supporting language. This is a new matter rejection. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-3, 5, 8, 10, 16, 21, 24, 27-28 and 31-34 is/are rejected under 35 U.S.C. 103 as being unpatentable over Smith et al. (US 2016/0303039; of record), evidenced by in view of Gizurarson et al. (US 2008/0275030; of record) and Gumudavelli et al. (US 2018/0169061; of record). Smith describes a transdermal cannabinoid formulation capable of diffusing into the bloodstream of the user. The composition is to comprise a cannabinoid compound, such as CBD or THC (see [0084]), in an amount between 0.01-5% by weight of the composition (see [0089]) (see instant claims 1-3). The cannabinoid is considered oil free as it is recited on its own as a single chemical compound, e.g. D9-tetrahydrocannaibinol, tetrahydrocannabinol, etc., and not combined or solvated with an oil (see instant claim 1). The composition may further include surfactants such as lecithin (ionic surfactant) in an of between 2-24% (see [0020]) (see instant claims 1, 8 and 28). Although the source of the lecithin is considered immaterial as lecithin’s structure is chemically conserved across sources, Smith teaches that the lecithin may be sourced from soy (i.e. soy lecithin) (see [0016]) (see instant claim 28). Smith’s composition may also include nonionic surfactants such as polysorbate 80 in an amount of between 0.5-3% by weight (see [0025-0026]) (see instant claims 1, 5 and 27). Penetration enhancers, such as diethylene glycol monomethyl ether and isopropyl myristate in an amount of between 1-40% (see [0035. 0036]). Sensates such as terpenes are also envisaged in amounts between 0.01-20% (see [0056] (see instant claims 1, 21 and 33) and humectants such as glycerin (i.e. glycerol) (‘clarifying solubilizer’) are present in an amount of between 1-10% by weight (see [0035, 0037]) (see instant claims 1 and 32). Methods of administering the cannabinoid composition are contemplated by administering an effective amount of the composition (see abstract and [0092]). Smith fails to include a partitioning solubilizer (e.g. dimethyl isosorbide) in an amount of between 0.001-80% by weight and a clarifying solubilizer (e.g. b-cyclodextrin) in an amount between 0.01-80%, Gizurarson describes a composition for delivering a therapeutic agent (e.g. tetrahydrocannibol, a cannabinoid; see [0053]) that is poorly soluble. The formulation includes various excipients such as absorption promoters which includes beta-cyclodextrin (a clathrate solubilizer) (see [0061]) (see instant claims 1 and 31) and solubilizers that act to enhance the solubility of the poorly soluble therapeutic substances. Exemplified solubilizers include diethylene glycol monoethyl ether (i.e. transcutol) and dimethyl isosorbide (‘second partitioning solubilizer’) and are taught to be present in an amount of between 0.1-50% (see [0062, 0063]) (see instant claims 1 and 13). See MPEP 214.05(I) regarding the obviousness of overlapping ranges. It would have been obvious to modify Smith to include the solubilizers taught by Gizurarson (e.g. dimethyl isosorbide, etc.) to improve the solubility profile and delivery of the poorly soluble therapeutic agent. Gumadavelli is directed to tetrahydrocannabinol compositions that are formulated to exhibit improved stability, dissolution and bioavailability wherein the composition comprises absorption enhancers such as cyclodextrins which are present in an amount of between 0.01-5% by weight (see [0037]) (see instant claims 1 and 16). It would have been obvious to use this amount of cyclodextrin in the combination of Smith and Gizurarson with a reasonable expectation for success in improving the absorptive activity of the cannabinoid solubilized in the composition. See MPEP 2143(I)(A) which states that combining prior art elements according to known methods to yield predictable results is indicia of obviousness. Regarding the claimed composition being ‘self-emulsifying’, this property would be expected to occur upon arriving at the obvious composition as suggested from the prior art. Regarding instant claim 24, although this claim is unclear (see above), the combination of Smith and Gizurarson teach a total surfactant (ionic and nonionic) of between about 2.5-27% by weight and a total solubilizer of between 0.01-5%. Formulating a composition having 5% the solubilizer component and 2.5% the surfactant component would result in a ratio of 2:1 which is within that being claimed. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). Regarding instant claim 6, the ratio of the weight of the cannabinoid to the volume of the formulation would be expected to follow from the prior art given the overlap in the weight percentage the cannabinoid comprises the composition. The prior art describes a composition that contains between 0.01-5% whereas instant claim 1 requires 0.001-40%. Thus, as the weight percentages overlap it would be the case the ratio of weight to volume must also overlap. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Show 2 earlier events
Jan 13, 2025
Non-Final Rejection mailed — §103, §112
Jul 14, 2025
Response Filed
Oct 17, 2025
Final Rejection mailed — §103, §112
Apr 17, 2026
Response after Non-Final Action
Apr 30, 2026
Applicant Interview (Telephonic)
May 22, 2026
Request for Continued Examination
Jun 11, 2026
Response after Non-Final Action
Oct 19, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778134
COMPOSTABLE ANTI-MICROBIAL FILM AND METHOD OF APPLYING FILM TO PACKAGING
4y 2m to grant Granted Nov 03, 2026
Patent 12779008
PROCESS FOR PURIFICATION OF MITRAGYNINE
3y 6m to grant Granted Nov 03, 2026
Patent 12767635
LIPOXYGENASE INHIBITORS
4y 1m to grant Granted Oct 20, 2026
Patent 12765549
METHOD OF USING/APPLYING A KERATIN HYDROLYSIS PEPTIDE SOLUTION TO PROMOTE TOLERANCE OF SOYBEAN AND ITS GROWTH UNDER STRESS OF FLOODING
2y 5m to grant Granted Oct 20, 2026
Patent 12758677
MATERIALS AND METHODS FOR DEODORIZATION OF MAMMALIAN URINE
2y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
41%
Grant Probability
77%
With Interview (+35.7%)
4y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1002 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month